Vor Biopharma (NASDAQ:VOR) Price Target Raised to $27.00

Vor Biopharma (NASDAQ:VOR) had its price objective boosted by Wedbush from $18.00 to $27.00 in a report issued on Wednesday,Benzinga reports. Wedbush currently has a neutral rating on the stock.

A number of other research firms have also weighed in on VOR. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.38.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $23.03 on Wednesday. The firm has a fifty day simple moving average of $18.55 and a two-hundred day simple moving average of $16.01. Vor Biopharma has a 12 month low of $6.50 and a 12 month high of $50.20.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, analysts predict that Vor Biopharma will post -2.7 earnings per share for the current year.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently made changes to their positions in the stock. RA Capital Management L.P. grew its position in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. lifted its holdings in Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Vor Biopharma during the 4th quarter worth about $33,275,000. Paradigm Biocapital Advisors LP bought a new position in Vor Biopharma in the 4th quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP bought a new position in Vor Biopharma in the 4th quarter worth about $13,080,000. 97.29% of the stock is owned by institutional investors.

Key Vor Biopharma News

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target to $27. The higher target provides additional support for the stock’s valuation and reflects continued optimism about Vor Biopharma’s long-term prospects. Wedbush Increases Vor Biopharma Price Target to $27.00
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $31 price target. The firm expects continued losses in the near term, including estimated 2027 EPS of negative $3.65, but projects a return to profitability by 2029 at $1.33 EPS. Its estimates imply that the investment case remains dependent on successful clinical and commercial execution.
• Negative Sentiment: HC Wainwright lowered several future earnings forecasts. The firm reduced its Q3 2026 EPS estimate to negative $0.91 from negative $0.70 and its Q4 2026 estimate to negative $0.94 from negative $0.72. It also cut full-year 2027 EPS to negative $3.65 from negative $2.78, full-year 2028 EPS to negative $2.61 from negative $1.67, and full-year 2029 EPS to $1.33 from $1.86. These revisions suggest higher expected losses and a slower path to profitability.
• Negative Sentiment: Recent quarterly results missed expectations. Vor reported a quarterly loss of $0.80 per share versus the consensus estimate of a $0.69 loss, an unfavorable earnings surprise that pressured the stock. Analysts expect the company to remain unprofitable during the current fiscal year. Vor Biopharma Stock Price Down Following Weak Earnings

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).